Published November 19, 2020 | Version v1

Non-viral Gene Delivery Methods for Bone and Joints

  • 1. Tissue Engineering for Orthopaedics and Mechanobiology, Department for BioMedical Research (DBMR), Faculty of Medicine, University of Bern, Bern, Switzerland; Department of Orthopaedic Surgery and Traumatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
  • 2. Department of Biomedical Engineering and Department of Orthopaedics, Spine Research Institute Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, United States
  • 3. Department of Biomedical Engineering and Department of Surgery, Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, United States
  • 4. Department of Pulmonary Medicine, Inselspital, University Hospital, University of Bern, Bern, Switzerland

Description

Viral carrier transport efficiency of gene delivery is high, depending on the
type of vector. However, viral delivery poses significant safety concerns such as
inefficient/unpredictable reprogramming outcomes, genomic integration, as well as
unwarranted immune responses and toxicity. Thus, non-viral gene delivery methods
are more feasible for translation as these allow safer delivery of genes and can
modulate gene expression transiently both in vivo, ex vivo, and in vitro. Based on
current studies, the efficiency of these technologies appears to be more limited, but
they are appealing for clinical translation. This review presents a summary of recent
advancements in orthopedics, where primarily bone and joints from the musculoskeletal
apparatus were targeted. In connective tissues, which are known to have a poor
healing capacity, and have a relatively low cell-density, i.e., articular cartilage, bone,
and the intervertebral disk (IVD) several approaches have recently been undertaken. We
provide a brief overview of the existing technologies, using nano-spheres/engineered
vesicles, lipofection, and in vivo electroporation. Here, delivery for microRNA (miRNA),
and silencing RNA (siRNA) and DNA plasmids will be discussed. Recent studies will
be summarized that aimed to improve regeneration of these tissues, involving the
delivery of bone morphogenic proteins (BMPs), such as BMP2 for improvement of bone
healing. For articular cartilage/osteochondral junction, non-viral methods concentrate on
targeted delivery to chondrocytes or MSCs for tissue engineering-based approaches.
For the IVD, growth factors such as GDF5 or GDF6 or developmental transcription
factors such as Brachyury or FOXF1 seem to be of high clinical interest. However, the
most efficient method of gene transfer is still elusive, as several preclinical studies have
reported many different non-viral methods and clinical translation of these techniques
still needs to be validated. Here we discuss the non-viral methods applied for bone and
joint and propose methods that can be promising in clinical use.

Notes

Financial support was received from iPSpine H2020 project under the grant agreement #825925, the Swiss National Science Foundation Project 310030E_192674/1, and by an International Training Network (ITN) "Disc4all" under the grant agreement #955735, all assigned to BG. Financial support was also received from National Institutes of Health via NIAMS R61AR0767861 award assigned to DP and NH-C.

Files

fbioe-08-598466.pdf

Files (3.5 MB)

Name Size Download all
md5:b0b52a7df447b9e6efc7063720a02947
3.5 MB Preview Download

Additional details

Funding

European Commission
iPSpine - Induced pluripotent stem cell-based therapy for spinal regeneration 825925